Physician profile
Steven Sikalis
NPI 1427034263
$3,129.96
in general payments reported to CMS, 2019-2025
20 companies · $698 in 2025
The $698 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $227 · 2021: $506 · 2022: $524 · 2023: $307 · 2024: $549 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $421.14 | 2019-2025 | Clariti Contact Lens, Misight Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $390.00 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $381.64 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $278.31 | 2019-2021 | |
| Alcon Vision LLC | $247.28 | 2019-2025 | Tryptyr, Rocklatan |
| Glaukos Corporation | $178.44 | 2023-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Sight Sciences, INC. | $177.34 | 2019-2024 | Tearcare System |
| Heru, INC. | $142.04 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $126.49 | 2020-2025 | |
| Allergan, INC. | $119.54 | 2021 | |
| Biotissue Holdings INC. | $101.18 | 2024 | |
| Menicon America INC | $98.04 | 2022 | |
| Optovue, INC. | $95.92 | 2019-2020 | |
| Oyster Point Pharma, INC. | $81.79 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $70.23 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.22 | 2019-2021 | |
| Shire North American Group INC | $46.37 | 2019 | |
| Abbvie INC. | $44.18 | 2022 | |
| Astellas Pharma US INC | $43.55 | 2024 | Izervay |
| Lombart Brothers, INC. | $23.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Sikalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.